Evolution of the Average Target: DSM-Firmenich

Evolution of the Target Price: DSM-Firmenich

Changes in Analyst Recommendations: DSM-Firmenich

9be3a559.R1Q3E6zTwalXoCZt19vwqOBt4bAWxG2hOZ4f-H66mhI.LRdjetqrjJ0Bwws5vrrHz7NZid5m9Qj-bdhyiQ7U42cgGwdRyZWOxg3Xcw~904ed45378b1d67d700c33eb1f58aeb2
08-18 KBC Securities Downgrades DSM-Firmenich to Hold MT
08-12 Kempen Downgrades DSM-Firmenich to Sell, Boosts PT MT
08-10 Oddo BHF Boosts DSM-Firmenich PT, Maintains Outperform Rating MT
08-06 Equita SIM Downgrades DSM-Firmenich to Hold, Raises PT MT
07-30 DSM-Firmenich: Volume inflection validated the strategy Alphavalue
06-19 AlphaValue/Baader Europe Downgrades DSM-Firmenich to Reduce, Lifts PT MT
06-09 AlphaValue/Baader Europe Upgrades DSM-Firmenich to Add, Lifts PT MT
06-08 Goldman Sachs Downgrades DSM-Firmenich to Sell, Cuts PT MT
05-22 AlphaValue/Baader Europe Downgrades DSM-Firmenich to Reduce, Lifts PT MT
05-22 Swiss stocks - Factors to watch on May 22 RE
05-06 DSM-Firmenich: Volumes deliver, margin to follow Alphavalue
04-28 KBC Securities weighs in on DSM-Firmenich divestment Zonebourse
03-18 KBC Securities Still Positive on DSM-Firmenich Zonebourse
03-17 Sulfur and methanol prices soar on Middle East conflict Alphavalue
03-13 DSM-Firmenich ready to step up the pace and hit its mid-term targets Zonebourse
03-12 DSM-Firmenich: The story moves from restructuring to delivery Alphavalue
03-11 Kempen Downgrades DSM-Firmenich to Neutral, Cuts PT MT
03-04 Middle East tensions intensify pessimism in chemicals Alphavalue
02-26 AlphaValue/Baader Europe Adjusts Rating, Estimates for DSM-Firmenich on Sale of Animal Nutrition, Health Unit MT
02-25 DSM-Firmenich: ANH Divestment at a Discount May Unlock Growth Potential Alphavalue
02-13 Kepler Cheuvreux Downgrades DSM-Firmenich to Hold, Cuts PT MT
02-12 DSM-Firmenich: Profitability disappoints in FY25 Alphavalue
02-09 DSM-FIRMENICH : Jefferies reaffirms its Buy rating ZD
12-30 Berenberg Reduces DSM-Firmenich PT, Keeps Buy Rating MT
12-30 Berenberg Expects DSM-Firmenich to Retain Minority Stake in Vitamins Business Amid 'Protracted' Deal Talks MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-2.86%
+5.48%
+15.17%
+6.44%
+33.68%
+7.77%
+22.03%
+21.46%
- - -5.81%
Average +11.48%
Weighted average by Cap. +9.07%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
95.30EUR
Average target price
92.57EUR
Spread / Average Target
-2.86%
High Price Target
106.00EUR
Spread / Highest target
+11.23%
Low Price Target
67.00EUR
Spread / Lowest Target
-29.70%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
AA
  1. Stock Market
  2. Stocks
  3. DSFIR Stock
  4. Consensus DSM-Firmenich